The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

  • End date
    Aug 1, 2025
  • participants needed
  • sponsor
    Chinese PLA General Hospital
Updated on 24 January 2021
cell transplantation
classical hodgkin lymphoma
refractory hodgkin lymphoma


This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin Lymphoma who were confirmed resistant to Anti-PD-1 antibody therapy.

Condition Hodgkin's Disease, Lymphoma, Anti-PD-1 Antibody Resistant, Anti-PD-1 Antibody Resistant, Anti-PD-1 Antibody Resistant, hodgkin, hodgkin's lymphomas, hodgkin lymphomas, hodgkins lymphoma, hodgkin's lymphoma, Anti-PD-1 Antibody Resistant
Treatment Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab
Clinical Study IdentifierNCT04514081
SponsorChinese PLA General Hospital
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Subjects must have histological confirmation of relapsed or refractory Hodgkin lymphoma (HL)
12 to 75 years of age
ECOG performance of less than 2
Life expectancy of at least 3 months
Subjects with lymphoma must have at least one measureable lesion >1 cm as defined by lymphoma response criteria
Subjects must have received Anti-PD-1 antibody therapy and were confirmed Anti-PD-1 antibody resistant. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months
Subjects must have adequate marrow, live, renal and heart functions

Exclusion Criteria

Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications
Serious uncontrolled medical disorders or active infections, pulmonary infection especially
Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1 month
Prior organ allograft
Women who are pregnant or breastfeeding
Women with a positive pregnancy test on enrollment or prior to investigational product administration
Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note